Literature DB >> 10447731

Do self-perpetuating B lymphocytes drive human autoimmune disease?

J C Edwards1, G Cambridge, V M Abrahams.   

Abstract

Normal immunological memory is thought to be underpinned by T lymphocytes. However, in rheumatoid arthritis there are indications that T-lymphocyte control has been subverted by self-perpetuating B lymphocytes. Potential mechanisms in other autoimmune states are less clear, but a number of observations suggest that misappropriation of immunological memory by B lymphocytes may be a common feature of human autoantibody-associated disease. Put simply, autoantibodies drive their own production. If so, the availability of safe B-lymphocyte-depleting agents provides a potential means for reversal of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447731      PMCID: PMC2326840          DOI: 10.1046/j.1365-2567.1999.00772.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Cross-linking of both Fc gamma RI and Fc gamma RII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-Fc gamma R interactions. Functional activation of Fc gamma RII by treatment with proteases or neuraminidase.

Authors:  J M Debets; J G Van de Winkel; J L Ceuppens; I E Dieteren; W A Buurman
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

2.  Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.

Authors:  H H Guldner; C Szostecki; H P Vosberg; H J Lakomek; E Penner; F A Bautz
Journal:  Chromosoma       Date:  1986       Impact factor: 4.316

Review 3.  Hypergammaglobulinemic purpura. Studies on the unusual anti- -globulins characteristic of the sera of these patients.

Authors:  J D Capra; R J Winchester; H G Kunkel
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

4.  The Fc valency of an immune complex is the decisive factor for binding to low-affinity Fc gamma receptors.

Authors:  R J Klaassen; R Goldschmeding; P A Tetteroo; A E Von dem Borne
Journal:  Eur J Immunol       Date:  1988-09       Impact factor: 5.532

5.  Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid.

Authors:  M J Welch; S Fong; J Vaughan; D Carson
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

Review 6.  The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis.

Authors:  W W Tourtellotte; M J Walsh; R W Baumhefner; S M Staugaitis; P Shapshak
Journal:  Ann N Y Acad Sci       Date:  1984       Impact factor: 5.691

7.  Anticarbohydrate autoantibodies to sialidase-treated erythrocytes and thymocytes in serum from patients with pulmonary sarcoidosis.

Authors:  Y Pilatte; E M Tisserand; A Greffard; J Bignon; C R Lambré
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

8.  Differential distribution of Fc gamma RIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments.

Authors:  A Bhatia; S Blades; G Cambridge; J C Edwards
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 9.  IgG rheumatoid factors and self-association of these antibodies.

Authors:  M Mannik; F A Nardella
Journal:  Clin Rheum Dis       Date:  1985-12

10.  Microenvironment of thymic myoid cells in myasthenia gravis.

Authors:  T Kirchner; F Hoppe; B Schalke; H K Müller-Hermelink
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1988
View more
  32 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 2.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

Review 4.  How does B cell depletion therapy work, and how can it be improved?

Authors:  E A Clark; J A Ledbetter
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 5.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

Review 6.  B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.

Authors:  R John Looney
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.

Authors:  Rina Bhatt; Christine C Nelson; Raymond S Douglas
Journal:  Saudi J Ophthalmol       Date:  2010-11-11

8.  Management of antiphospholipid syndrome.

Authors:  Nicoletta Del Papa; Nikoleta Vaso
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

Review 9.  Regulatory B cells in autoimmune diseases.

Authors:  Min Yang; Ke Rui; Shengjun Wang; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2013-01-07       Impact factor: 11.530

Review 10.  Roles of B cells in rheumatoid arthritis.

Authors:  Gregg J Silverman; Dennis A Carson
Journal:  Arthritis Res Ther       Date:  2003-12-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.